Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Basic Medicine
  4. Vol 1, Issue 2, 2023

The Value of Lymphocyte Subsets and Cytokines in Adult Minimally Change Disease

Download as PDF

DOI: 10.23977/medbm.2023.010208 | Downloads: 6 | Views: 254

Author(s)

Xiaomeng Zheng 1, Lin Duan 1, Chengbi Tong 1, Xiaodong Li 1, Xiaodan Liu 1

Affiliation(s)

1 Department of Clinical Laboratory, Afliated Hospital of Hebei University, Baoding, 071000, China

Corresponding Author

Lin Duan

ABSTRACT

Adult Minimal Change Disease (AMCD) is a common autoimmune disease, which is characterized by glomerular basement membrane injury, proteinuria, hematuria, and hypertension. Researchers have found that at present, the pathogenesis of AMCD is still unclear, and there is no effective treatment, so studying the pathogenesis and treatment of AMCD holds great practical significance. This paper mainly discusses the role of lymphocyte subsets and cytokines in AMCD, and the relationship and regulation between them. Firstly, the text expounds the importance of lymphocyte subsets and cytokines from the pathogenesis, disease development, and treatment response of AMCD. Then, it emphasizes the significance of the interaction and synergy between lymphocyte subsets and cytokines in AMCD, and the authors put forward a new strategy of targeted therapy for lymphocyte subsets and cytokines. Through an in-depth understanding of lymphocyte subsets, cytokines, and their relationship in AMCD, researchers can more clearly understand the pathogenesis, disease development, and the essence of treatment response of AMCD. Moreover, the targeted therapy strategy for lymphocyte subsets and cytokines also provides new ideas and methods for the clinical treatment of AMCD, which is helpful to improve the prognosis and quality of life of patients.

KEYWORDS

Adult Minimal Change Disease; Lymphocyte Subsets; Cytokines

CITE THIS PAPER

Xiaomeng Zheng, Lin Duan, Chengbi Tong, Xiaodong Li, Xiaodan Liu, The Value of Lymphocyte Subsets and Cytokines in Adult Minimally Change Disease. MEDS Basic Medicine (2023) Vol. 1: 47-51. DOI: http://dx.doi.org/10.23977/medbm.2023.010208.

REFERENCES

[1] Bixia G, Ningjing L, Suxia W, et al. Minimal change disease associated with anti-PD1 immunotherapy: a case report [J]. Bmc Nephrology, 2018, 19(1):156.
[2] Siligato, R, Cernaro, et al. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis [J]. Expert opinion on investigational drugs, 2018(7/12):27. 
[3] Tam W C, Lin C H, Chuang C Y, et al. Acute aortoiliac thrombosis due to minimal change disease[J]. Nephrology, 2018, 23(4):377-378
[4] Imran, S, Aigbe, et al. Conversion Of Minimal Change Disease To Focal Segmental Glomerlosclerosis In A Patient With Hodgkins Lymphoma [J]. Journal Of Investigative Medicine, 2018, 66(1):134-135. 
[5] Dado, David, Parikh, et al. Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept[J]. Clinical nephrology, 2018, 89(5):376-380. 
[6] Hosohata, Keiko. Can Focal Segmental Glomerulosclerosis Be Differentiated From Minimal Change Nephrotic Syndrome Using Biomarkers?[J]. American Journal of the Medical Sciences, 2018, 355(4):305.
[7] Chowdhary V R. When doing the right thing is wrong: Drug efflux pumps in steroid‐resistant nephrotic syndrome [J]. International Journal of Rheumatic Diseases, 2020, 23(5):611-612.
[8] Hafez A, Geddes C C. Impact of COVID-19 pandemic on the incidence of nephrotic syndrome in patients with minimal change disease and primary focal segmental glomerulosclerosis[J]. Scottish medical journal, 2021(2):66. 
[9] Jellouli M, Charfi R, Maalej B, et al. Rituximab in the Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review [J]. The Journal of Pediatrics, 2018, 197:191-197.
[10] Awanami Y, Fukuda M, Nonaka Y, et al. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report [J]. Bmc Nephrology, 2017, 18(1):221.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 427
Visits: 13277

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.